RAD-140 and YK-11 Interaction

Monitor
Researched 90% confidence

RAD-140 and YK-11 have an interaction requiring monitoring for interaction with 90% confidence. YK-11 and RAD-140 are sometimes stacked by users seeking to combine YK-11's myostatin inhibition with RAD-140's potent AR agonism. This combination compounds the risk of testosterone suppression and liver enzyme elevation, as both compounds are hepatically metabolized. If combining, comprehensive blood work (liver function, hormones, lipids) is essential at baseline, mid-cycle, and post-cycle. Liver support supplementation is strongly recommended. Both compounds affect the gonads and liver and heart, so monitoring these systems is recommended.

Compound Profiles

RAD-140

Selective Androgen Receptor Modulator | Investigational SARM

RAD-140 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a full agonist in muscle and bone tissue while exhibiting minimal agonist activity in the prostate and other androgen-sensitive tissues. This tissue selectivity is achieved through differential cofactor recruitment: upon binding to the AR, RAD-140 induces a conformational change that favors interaction with coactivators predominantly expressed in skeletal muscle and bone, rather than those prevalent in prostate or sebaceous glands.

Half-life: ~60 hours Typical dose: 10-20 mg/day sarm, anabolic
androgen receptorepo receptor androgenicblood pressure raisingcarcinogenic riskcrosses bbb
View full profile

YK-11

Myostatin Inhibitor & SARM Hybrid | Experimental

YK-11 exerts its effects through two distinct but complementary pathways. First, it acts as a partial agonist of the androgen receptor (AR).

Half-life: ~6-10 hours Typical dose: 5-10 mg/day sarm, anabolic
androgen receptorepo receptormyostatintgf beta androgenicblood pressure raisingcarcinogenic riskhepatotoxic
View full profile

Combined Organ Load

Gonads
elevated
Liver
elevated
Heart
moderate

Shared Safety Flags

2x 2 androgenic compounds (RAD-140, YK-11). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 compounds raise blood pressure (RAD-140, YK-11). Monitor BP daily and consider cardiovascular support.
2x 2 compounds share the carcinogenic-risk safety flag (RAD-140, YK-11). Monitor accordingly.
2x 2 hepatotoxic compounds (RAD-140, YK-11). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 HPTA-suppressive compounds (RAD-140, YK-11). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (RAD-140, YK-11). Get lipid panel mid-cycle — consider adding lipid support.

Frequently Asked Questions

Can I take RAD-140 with YK-11?

Yes, but with caution. YK-11 and RAD-140 are sometimes stacked by users seeking to combine YK-11's myostatin inhibition with RAD-140's potent AR agonism. This combination compounds the risk of testosterone suppression and liver enzyme elevation, as both compounds are hepatically metabolized. If combining, comprehensive blood work (liver function, hormones, lipids) is essential at baseline, mid-cycle, and post-cycle. Liver support supplementation is strongly recommended. Regular monitoring is advised.

Is RAD-140 and YK-11 safe together?

Based on documented research, this combination is considered monitor. However, shared safety flags include: androgenic, blood pressure raising, carcinogenic risk, hepatotoxic, hpta suppressive, lipid disrupting. Monitor accordingly.

What are the interactions between RAD-140 and YK-11?

YK-11 and RAD-140 are sometimes stacked by users seeking to combine YK-11's myostatin inhibition with RAD-140's potent AR agonism. This combination compounds the risk of testosterone suppression and liver enzyme elevation, as both compounds are hepatically metabolized. If combining, comprehensive blood work (liver function, hormones, lipids) is essential at baseline, mid-cycle, and post-cycle. Liver support supplementation is strongly recommended. This assessment has 90% confidence and is based on documented research data.

How should I time RAD-140 and YK-11?

RAD-140 has a half-life of ~60 hours and YK-11 has a half-life of ~6-10 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: RAD-140 vs YK-11

This interaction analysis is compiled from research literature and pharmacological mechanism data. Always consult a healthcare professional before combining compounds.